Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug eltrekibart aims to tame painful skin condition

NCT ID NCT06046729

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 6 times

Summary

This study tests a new drug called eltrekibart in 352 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and inflammation. Participants receive either the drug or a placebo for about 62 weeks. The goal is to find a safe and effective dose that reduces abscesses and pain, offering a potential new option for those who haven't improved with antibiotics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
eltrekibart (a drug given as an injection under the skin)
What this could lead to
If it works, this could point toward a new treatment option for people with moderate-to-severe hidradenitis suppurativa who haven't responded well to antibiotics.
What could go wrong
This is an early Phase 2b trial, so the drug may not prove effective or safe enough for wider use. The results are still uncertain, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

352 people

The number who actually took part.

Started

Oct 2023

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of HS for at least 12 months. * Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III. * Have an (abscess plus inflammatory nodule) count of at least 5. * Agree to use topical antiseptics daily. * Had an inadequate response or intolerance to a 28-day course of oral antibiotics. Exclusion Criteria: * Have more than 20 draining fistulae. * Have had surgical treatment for HS in the last 4 weeks before randomization. * Have an active skin disease or condition, that could interfere with the assessment of HS. * Have a current or recent acute, active infection. * Are immunocompromised. * Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

Contacts and locations

Locations

  • ActivMed Practices & Research, Inc.

    Portsmouth, New Hampshire, 03801, United States

  • Advanced Medical Research, PC

    Sandy Springs, Georgia, 30328, United States

  • Advanced Research Experts

    Nashville, Tennessee, 37211, United States

  • Alberta Dermasurgery Centre

    Edmonton, Alberta, T6G 1C3, Canada

  • Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • Alliance Clinical Research of Tampa

    Tampa, Florida, 33615, United States

  • Apex Clinical Research Center

    Mayfield Heights, Ohio, 44124, United States

  • Arkansas Research Trials, LLC

    North Little Rock, Arkansas, 72117, United States

  • Beacon Dermatology

    Calgary, Alberta, T3E 0B2, Canada

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Brunswick Dermatology Center

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Care Access-Marriottsville

    Marriottsville, Maryland, 21104, United States

  • Center For Dermatology Clinical Research, Inc.

    Fremont, California, 94538, United States

  • Center de Recherche St Louis

    Québec, Quebec, G1W 4R4, Canada

  • Centrum Medyczne Pratia Katowice

    Katowice, Silesian Voivodeship, 40-081, Poland

  • Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska

    Wroclaw, Lower Silesian Voivodeship, 50-566, Poland

  • Columbia Dermatology & Aesthetics

    Columbia, South Carolina, 29212-8623, United States

  • Darst Dermatology

    Charlotte, North Carolina, 28277-8014, United States

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250, United States

  • Derm Research LLC

    Louisville, Kentucky, 40217, United States

  • DermDox Centers for Dermatology

    Camp Hill, Pennsylvania, 17011, United States

  • DermDox Dermatology Centers

    Sugarloaf, Pennsylvania, 18249, United States

  • DermEffects - Probity - PPDS

    London, Ontario, N6H 5L5, Canada

  • Dermatology Institute and Skin Care Center

    Santa Monica, California, 90404, United States

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Dermatology Specialists of Charlotte

    Charlotte, North Carolina, 28277, United States

  • Dermatology Specialists of Spokane

    Spokane, Washington, 99202-1332, United States

  • Dermoklinika-Centrum Medyczne s.c

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Direct Helpers Research Center

    Hialeah, Florida, 33012, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710-3038, United States

  • East Sydney Doctors

    Darlinghurst, New South Wales, 2010, Australia

  • Equity Medical - Bowling Green

    Bowling Green, Kentucky, 42104, United States

  • First OC Dermatology Research Inc

    Fountain Valley, California, 92708, United States

  • ForCare Clinical Research

    Tampa, Florida, 33613-1244, United States

  • Fremantle Dermatology

    Fremantle, Western Australia, 6160, Australia

  • Hautarztpraxis Mahlow

    Blankenfelde-Mahlow, Brandenburg, 15827, Germany

  • Hautklinik Erlangen

    Erlangen, Bavaria, 91054, Germany

  • Hautzentrum Friedrichshain - Dermatologie

    Berlin, 10247, Germany

  • Holdsworth House Medical Practice

    Sydney, 2010, Australia

  • Hospital of Venereal and Skin Diseases A.Syggros

    Athens, Attica, 16121, Greece

  • International Clinical Research - Tennessee (IC Research)

    Murfreesboro, Tennessee, 37130, United States

  • Jordan Valley Dermatology Center

    South Jordan, Utah, 84095, United States

  • Klinika Badawcza Centrum Badan Klinicznych Wojciech Brzezicki

    Malbork, Pomeranian Voivodeship, 82-200, Poland

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Medical Dermatology Specialists

    Phoenix, Arizona, 85006, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Modern Research Associates

    Dallas, Texas, 75231, United States

  • North Texas Clinical Research

    Frisco, Texas, 75034, United States

  • NorthShore Medical Group Dermatology - Skokie

    Skokie, Illinois, 60077-1049, United States

  • Northwest Arkansas Clinical Trials Center

    Rogers, Arkansas, 72758, United States

  • Olympian Clinical Research

    Tampa, Florida, 33615, United States

  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji

    Warsaw, Masovian Voivodeship, 02-507, Poland

  • Papageorgiou General Hospital of Thessaloniki

    Thessaloniki, Thessaloníki, 56429, Greece

  • Revival Research Institute - Troy

    Troy, Michigan, 48084, United States

  • Saguaro Dermatology Associates, LLC - Probity - PPDS

    Phoenix, Arizona, 85008, United States

  • Simcoderm Medical & Surgical Dermatology Centre

    Barrie, Ontario, L4M 7G1, Canada

  • Sinclair Dermatology - East Melbourne

    East Melbourne, Victoria, 3002, Australia

  • Skin Research of South Florida

    Miami, Florida, 33173-1407, United States

  • Skin Specialists, P.C

    Omaha, Nebraska, 68144, United States

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575, Australia

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, 20251, Germany

  • Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital

    Bochum, North Rhine-Westphalia, 44791, Germany

  • University General Hospital of Heraklion Loc. 1

    Heraklion, Irakleío, 711 10, Greece

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Connecticut

    Farmington, Connecticut, 06032, United States

  • University of Miami

    Miami, Florida, 33125, United States

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Hesse, 60596, Germany

  • Universitätsklinikum Münster - Albert Schweitzer Campus

    Münster, Westfalen, 48149, Germany

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Pomeranian Voivodeship, 80-214, Poland

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

  • Wiseman Dermatology Research Inc.

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Wro Medica

    Wroclaw, Lower Silesian Voivodeship, 51-685, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.